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Digital imaging in the immunohistochemical
evaluation of the proliferation markers Ki67,
MCM2 and Geminin, in early breast cancer,
and their putative prognostic value
Shalaka Joshi1,2,4*†, Johnathan Watkins1,2†, Patrycja Gazinska1,2, John P. Brown1, Cheryl E. Gillett1,3,
Anita Grigoriadis1,2 and Sarah E. Pinder1,3
Abstract
Background: Immunohistochemical assessment of proliferation may provide additional prognostic information
in early breast cancer. However, due to a lack of methodological standards proliferation markers are still not
routinely used for determining therapy. Even for Ki67, one of the most widely-studied markers, disagreements
over the optimal cutoff exist. Improvements in digital microscopy may provide new avenues to standardise
and make data more reproducible.
Methods: We studied the immunohistochemical expression of three markers of proliferation: Ki67, Mini-Chromosome
Maintenance protein 2 and Geminin, by conventional light microscope and digital imaging on triplicate TMAs from 309
consecutive cases of primary breast cancers. Differences between the average and the maximum percentage reactivity in
tumour cell nuclei from the three TMA cores were investigated to assess the validity of the approach. Time-dependent
Receiver Operating Characteristic curves were utilized to obtain optimal expression level cut-offs, which were then
correlated with clinico-pathological features and survival.
Results: High concordance between conventional and digital scores was observed for all 3 markers
(Ki67: rs = 0.87, P < 0.001; MCM2: rs = 0.94, P < 0.001; and Geminin: rs = 0.86, P < 0.001; Spearman’s rank). There
was no significant difference according to the number of TMA cores included for either Ki67 or MCM2;
analysis of two or three cores produced comparable results. Higher levels of all three proliferation markers
were significantly associated with higher grade (P < 0.001) and ER-negativity (P < 0.001). Optimal prognostic
cut-offs for percentage expression in the tumour were 8 %, 12 and 2.33 % for Ki67, MCM2 and Geminin respectively.
All 3 proliferation marker cutoffs were predictive of 15-year breast cancer-specific survival in univariable Cox regression
analyses. In multivariable analysis only lymph node status (HR = 3.9, 95 % CI = 1.79-8.5, P = 0.0006) and histological grade
(HR = 1.84, 95 % CI = 1–3.38, P = 0.05) remained significantly prognostic.
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Conclusions: Here we show that. MCM2 is a more sensitive marker of proliferation than Ki67 and should be examined
in future studies, especially in the lymph node-negative, hormone receptor-positive subgroup. Further, digital
microscopy can be used effectively as a high-throughput method to evaluate immunohistochemical expression.
Keywords: Ki67, MCM2, Geminin, Proliferation, Digital microscopy, Immunohistochemistry, Survival analysis
Background
Breast cancer is a heterogeneous disease [1]. With earlier
detection and improved treatment options, breast
cancer-related mortality is decreasing, while the detec-
tion of early stage disease is on the rise [2]. Traditional
prognostic and predictive factors such as lymph node
status, histological grade, invasive tumour size, hormone
receptor (ER and PR) and HER2 status may be insuffi-
cient for prognosticating early stage disease [3, 4]. As
such, there is a need for better markers to categorise pri-
mary, operable breast cancers and reduce overtreatment
in those patients with a good prognosis, and offer more
aggressive treatment regimes to those in the poor prog-
nosis group.
Proliferation is one of the most fundamental prop-
erties of cancer [5]. Histological grade is an important
prognostic marker, which reflects proliferation status
by incorporating an assessment of mitotic rate. Other
methods of assessing proliferation, such as S-phase
fraction, mitotic activity index (MAI) and radionu-
cleotide labeling indices have limitations, and have
not proven to be of utility over and above the prog-
nostic value of histological grade, and consequently,
they have not been applied in clinical practice [6].
Ki67 has been one of the most extensively studied
proliferation markers since its discovery in the early
1980s [7]. Since the development of the MIB-1 anti-
body, immunohistochemical expression of Ki67 in
paraffin-embedded tissue has been shown in a num-
ber of studies to be prognostic and predictive of
treatment response in breast cancer [8–10].
Molecular profiling of breast cancer can be used to
classify early breast cancer into prognostic groups [1].
Ki67 measured by immunohistochemistry (IHC) has
been proposed to be a useful surrogate for molecular
subtype. Ki67 at a cut-off of 13.25 % can identify and
divide ER-positive breast cancers into the luminal A and
B subgroups with moderate accuracy and with a signifi-
cant difference in patient survival [11]. As a result, the
St Gallen guidelines recommend a cut-off of 14 % for
Ki67 in deciding how to manage early breast cancer pa-
tients in the adjuvant treatment setting [12]. Other stud-
ies have reported that immunohistochemical analysis of
ER, PR, HER-2 and Ki67 (the latter at a cut-off of 10 %),
and a derived IHC-4 score is equivalent to the 21-gene
recurrence score that is the basis of Oncotype-DX in
predicting recurrence and survival in ER-positive breast
cancer [13, 14]. Currently, trials are underway to stratify
hormone receptor-positive, early breast cancer patients
by their gene expression profile into those with a low or
high risk of recurrence [15], which in turn influences the
decision to administer chemotherapy. Of note, 5 of the
21 genes assessed in Oncotype-DX are proliferation
genes, emphasising the importance of proliferation sta-
tus in tumour prognostication and in clinical decision
making [16]. Gwin et al. studied the correlation of Ki67
expression assessed by IHC in 32 breast cancer patients
for possible association with the Oncotype-DX’s recur-
rence score (RS) and found it to be high in some of the
low RS cases, as a result of which they suggested that
Ki67 be used alongside the RS [17].
Other markers of proliferation have been identified as
participants in the process of DNA replication as well as
exhibiting prognostic value. Mini-chromosome mainten-
ance (MCM) proteins are DNA helicases that, along with
the Origin Recognition Complex (ORC) and Cdc6p, form
the pre-Replication Complex (pre-RC), to initiate DNA
replication [18]. The dissociation of MCM proteins from
the pre-RC is controlled by Geminin, which prevents re-
replication by inhibiting Cdt-1 [19]. The immunohisto-
chemical expression of these proteins has been correlated
with prognosis in breast and other cancers [20–22].
However, methodological variability in assessing
these proliferation markers represents one of the
main difficulties for translating these research findings
into the clinic. Consequently, in an attempt to stand-
ardise the technique, the “International Ki67 in Breast
Cancer Working Group” has drafted guidelines for
the immunohistochemical assessment of Ki67 [23].
Adhering to these criteria, we carried out a study to
evaluate two different methods of assessing Ki67,
MCM2 and Geminin IHC in tissue microarrays
(TMAs) of a series of consecutive invasive breast can-
cer cases. We aimed to evaluate the concordance be-
tween conventional microscopic methods (i.e. the
histological sections) and digital scanned images from
the same material applied to three markers of prolif-
eration. Having evaluated the similarity between the
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two scoring methodologies, we sought to compare the
expression patterns of the three proliferation markers
with each other in order to establish their ability to
capture tumour proliferation status, as well as to de-
termine their association with clinico-pathological
characteristics.
Methods
Patients
Formalin-fixed paraffin-embedded (FFPE) tissue blocks
were retrieved from 309 patients who presented with
primary invasive breast cancer between December 1989
and September 1992 to Guy’s and St Thomas’ Breast
Unit. Unless there was insufficient tissue for research
purposes, consecutive cases were selected, All patients
were treated surgically, either in the form of modified
radical mastectomy or breast conservation surgery,
followed by adjuvant treatment. Written, informed con-
sent was obtained before procuring the tissue for re-
search purposes. Permission to use samples and data
was given by the Cancer Biobank Access Committee
(License number 12121) in accordance with NHS Re-
search Ethics Committee conditions.
Tissue Microarrays (TMAs) and Immunohistochemistry
(IHC)
Tissue samples were uniformly fixed in 10 % formalin
within 30 min of surgery. Representative areas were marked
on H & E sections for TMA construction. TMAs were
made in triplicate using a manual arrayer (Beecher Instru-
ments, Sun Prairie, WI, USA) with 0.6 mm stylet. Each
TMA consisted of 85–115 tissue cores, with 5 cores of con-
trol tissue samples placed strategically within the block to
enable orientation. Sections were cut at 3 μm and floated
onto polyanionic slides before being dried at 37 °C over-
night followed by incubation for 2 h at 56 °C. The TMA
sections were obtained during the study and freshly stained,
as per the recommendations. They were then incubated
with the antibodies after establishing appropriate IHC pro-
tocols. A two-step, compact, polymer chain, biotin-free
IHC protocol on the BOND-MAXTM (Leica Biosystems,
UK) staining system was used with a primary antibody in-
cubation time of 30 min. Antigen retrieval was performed
using BOND-MAX Epitope Retrieval solution 1 (Leica Bio-
systems, UK). The chromogen used was 3,3′-diaminobenzi-
dine (DAB). ER and HER2 status were obtained from
patient records. The antibodies are listed in Table 1.
Scoring the immunohistochemical expression of
proliferation markers: conventional and digital imaging
For each of the three markers, a score was determined
by assessment of the percentage of invasive carcinoma
cells with positively staining nuclei. At least 50 tumour
cells per TMA core were considered necessary to ascer-
tain a representative score. Any cores that were folded,
absent, or contained an inadequate number of tumour
cells were not scored. Conventional scoring was con-
ducted with an Olympus BX50 microscope (Olympus
Optical Co., Ltd., Tokyo, Japan) by the first author (SJ)
after a period of training and joint scoring.
Slides were subsequently scanned using a Nanozoomer
(Hammamatsu, UK), transferred to the digital slide ser-
ver and accessed online via the Slidepath system (Leica
Biosystems, UK). Digital microscopic scoring was per-
formed with the OpTMA scoring software platform
(Leica Biosystems, UK) and the percentage of positive
nuclei was again assessed similarly to the light micro-
scopic slides. Scoring using each of the two methods
was performed independently by the same reader (SJ),
one method at a time, and blinded to the results of as-
sessment by the other method. Approximately 10 % of
the scores were assessed by more than one author (SJ,
JB, PG) and there was in general good agreement among
the authors. Since the TMAs were assessed in triplicate,
both the maximum (from the 3 cores) and the average
of the 3 scores were recorded for final analysis.
Statistical methods
Where tumours were categorised into two continuous
groups, the significance of associations of each of the im-
munohistochemical scores was assessed with a Mann
Whitney test. For clinico-pathological features that
grouped tumours into three or more continuous, unpaired
categories, a Kruskal-Wallis test was used to assess associ-
ation. To analyse associations between two continuous
variables, Spearman’s rank correlation was applied.
Table 1 Antibody panel used for immunohistochemistry
Antigen Clone Dilution Source System Scoring method
Ki67 MIB1 1 in 75 Leica Leica, BOND-Max As described
MCM2 CRCT2.1 1 in 100 Leica Leica, BOND-Max As described
Geminin EM6 1 in 30 Leica Leica, BOND-Max As described
ER SP6 1 in 100 Invitrogen Leica, BOND-Max >2 Allred
HER2 Ready to use kit Leica Leica, BOND-Max 3+
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Wilcoxon signed rank test and Friedman’s test were used
to evaluate continuous, paired variables of 2 and 3 groups,
respectively. All the above statistics were performed using
GraphPad PRISM Version 6.0c (GraphPad Software, Inc,
CA, USA).
In order to establish a cut-off between high and low
expression that enabled the most accurate prediction of
breast cancer-specific survival (BCSS) for each of the
markers, time-dependent Receiver Operating Character-
istic (ROC) curves were created from the censored sur-
vival data using the Kaplan-Meier method with the R
package survivalRO [24]. The sensitivity and specificity
for predicting 15-year BCSS were calculated for various
cut-off values using a statistically-determined baseline
marker value as reference [25]. The value that yielded
the highest balanced accuracy, defined as (sensitivity +
specificity)/2, was selected as the optimal cut-off value.
Using the defined cut-off values to categorise cases
into high-expressing and low-expressing tumours,
Kaplan-Meier survival curves were constructed and
compared using the log-rank test for each marker. BCSS
was defined as the interval from the date of histological
diagnosis to the date of death due to breast cancer up
until 15 years. All other causes of death, including those
cases where the cause was unknown or was ambiguous,
were censored at the last follow-up.
Multivariable analysis was conducted using Cox’s
regression model with backward stepwise model se-
lection of predictors using the Akaike Information
Criterion [26]. The initial set of predictors for the
multivariable model included histological grade (1, 2
or 3), age (>50 years or <50 years), lymph node sta-
tus (positive or negative), clinical tumour size
(<2 cm, 2–5 cm or >5 cm), ER status (Allred > 2 as
positive) and HER2 status (positive if scored 3+ on
IHC or FISH positive). Multivariable analysis was
then conducted as before. Subgroup univariable and
multivariable survival analyses on ER-positive cases
were conducted similarly. All survival analysis was
performed in the statistical language R and is pro-
vided as a Sweave document in Supplementary
Methods (Additional file 3). In all statistical tests,
P < 0.05 was considered significant.
Results
Patient and tumour characteristics
Patient and tumour characteristics are shown in Table 2.
In this series of 309 cases, 70.1 % of patients were over
50 years of age, 53.8 % had lymph node-negative disease,
75.6 % were ER-positive and 16.8 % were HER2-positive
(although HER2 status was known for only 50 % of pa-
tients in this historical cohort). 43.4 % were of histo-
logical grade 2 and 55.4 % were between 2 and 5 cm in
size. The median follow-up period was 13 years (1 to
17.2 years). The median overall survival was 13.48 years
(0.3 to 18.1 years). There were 160 patients who died
(51.8 %) at the end of the follow up period, only 83 of
whom were known to have died of breast cancer.
Correlation between proliferation markers and
methodology
To explore the information provided by the scores for
each marker, we first compared them across the cohort.
We found that a greater proportion of tumour cells
showed expression of MCM2 than Ki67 and Geminin,
with the latter having the lowest frequency of expression
(P < 0.001; Wilcoxon signed rank test). The median light
microscopic scores of Ki67, MCM2 and Geminin when
using the maximum score from the 3 TMA cores, were
10 %, 30 and 5 %, respectively. With the mean light
microscopic score from the 3 cores, the median values
of Ki67, MCM2 and Geminin expression were 7.7 %, 24
and 3 %, respectively. With the digital scoring technique,
the medians of the maximum scores from the 3 TMA
cores were 7 %, 37 and 2 % whereas the medians of the
average 3 scores were 4.5 %, 27 and 2 % for Ki67,
MCM2 and Geminin, respectively (Table 3). Representa-
tive cores with staining for Ki67, MCM2 and Geminin
are shown in Fig. 1a-b, e-f and i-j, respectively. Fre-
quency distribution curves for the average Ki67, MCM2
and Geminin scores are shown in Fig. 1c, g and k,
respectively.
In order to assess inter-core variability within a sam-
ple, we compared the expression of Ki67 (110 cases),
MCM2 (116 cases) and Geminin (105 cases) across
those samples for which all 3 cores were available and
found no significant difference for Ki67 or MCM2,
(P = 0.411 for Ki67, P = 0.322 for MCM2; Friedman’s
test) indicating that Ki67 and MCM2 expression was
consistent across the 3 cores. In contrast, the inter-
core variability for Geminin was significantly higher
(P < 0.006; Friedman’s test). Of note, the average of 2
cores provided comparable results to the average
values of 3 cores (Ki67: rs = 0.96, P < 0.0001; MCM2:
rs = 0.95, P < 0.0001; Geminin: rs = 0.95, P < 0.0001)
suggesting that one may evaluate 2 or 3 cores for
such IHC markers. We also observed that the loss of
data due to core loss or absence of sufficient tumour,
decreased from 37−40 % to 22 and 16 %, if 1, 2 or 3 cores
were considered respectively for all 3 proliferation markers.
The average of the values obtained from 3 cores
strongly correlated with the maximum of the 3 (Ki67:
rs = 0.97, P < 0001; MCM2: rs = 0.98, P < 0.0001; Gemi-
nin: rs = 0.98, P < 0.0001). Since there was little differ-
ence between the average and maximum value obtained
from 3 cores; we proceeded with the average value for
further analysis.
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Comparison between conventional light microscopic and
digital image assessment
We next asked whether there was any appreciable differ-
ence between the results obtained from scoring the sec-
tion using the traditional light microscope as opposed to
assessment of the scanned digital image. A significant
correlation between the scores of the two techniques
was observed for each marker (Ki67: rs = 0.87, P < 0.001,
Fig. 1d; MCM2: rs = 0.94, P < 0.001 Fig. 1h; and Geminin:
rs = 0.86, P < 0.001, Fig. 1l; Spearman’s rank correlation),
with the scores for MCM2 exhibiting the highest
concordance.
Association with clinico-pathological features and BCSS
We investigated whether the immunohistochemical ex-
pression of Ki67, MCM2 and Geminin was significantly
associated with clinico-pathological features. These ana-
lyses were performed using the median value of both the
maximum as well as the average values of three TMA
cores scores and no significant difference between these
two approaches was observed. Whilst tumour size,
lymph node status and HER2 status were not associated
with any of the three proliferation markers, higher histo-
logical grade and ER-negative tumours had higher ex-
pressions of all 3 markers, P < 0.001 for all, Mann
Whitney test (Table 4).
Next we investigated if any of the three markers of
proliferation possessed prognostic value in our cohort by
first using time-dependent ROC curves to calculate cut-
offs that yielded the highest balanced accuracy for 15-
year BCSS. These cut-offs were 8 %, 12 and 2.33 % for
Ki67, MCM2 and Geminin, respectively (ROC curves for
cut-off calculation are shown in Fig. 2b, d and f ). In
a univariable Cox regression analysis, high expression
of all 3 markers of proliferation was significantly asso-
ciated with 15 year BCSS using optimal cut-off values
for Ki67 {P = 0.0142, HR = 0.55 (0.34−0.89); log-rank
test showing 95 % confidence intervals} (Fig. 2a); for
MCM2 {P = 0.0005, HR = 0.27 (0.12−0.59); log-rank
test showing 95 % confidence intervals} (Fig. 2c); and
for Geminin {P = 0.0072, HR = 0.51 (0.31−0.84); log-
rank test showing 95 % confidence intervals} (Fig. 2e).
To offset some of the heterogeneity that arises from
the inclusion of ER/PR negative cases in a consecutive
series of patients, we next used the same expression cut-
offs and looked within the ER-positive subgroup. We re-
capitulated the results seen in the wider cohort with
Table 2 Patient and tumour characteristics of 309 cases of early
breast cancer
Clinico-pathological feature Distribution (percentage of cases
with data)
Age, years
Median 58
Range 28−85
<50 92 (29.9 %)
>50 216 (70.1 %)
Tumour size
<2 cm 114 (41.3 %)
2−5 cm 153 (55.4 %)
>5 cm 9 (3.3 %)
Not known 33
LN status
Positive 132 (46.2 %)
Negative 154 (53.8 %)
Not known 23
Histological Grade
1 56 (20.1 %)
2 121 (43.4 %)
3 102 (36.6 %)
Not known 30
ER (Estrogen Receptor) status
Positive 226 (75.6 %)
Negative 73 (24.4 %)
Not known 10
HER2 status (IHC 3+ or FISH + ve)
Positive 26 (16.8 %)
Negative 129 (83.2 %)
Not known 154
Recurrence (Local, regional, distant
or death when death was known to
be caused by breast cancer)
Total 111/309 (35.9 %)
Median time to recurrence (years) 3.14
Range (years) 0.05−19.05
Mortality
Total deaths with known cause 148
Deaths due to breast cancer 83 (56 %)
Deaths with breast cancer present
at death
57 (38.5 %)
Deaths due to causes other than
breast cancer
8 (5.4 %)
Not known 12
Overall survival (years)
Median 13.48
Range 0.33−18.11
Table 2 Patient and tumour characteristics of 309 cases of early
breast cancer (Continued)
Follow-up (years)
Median 13
Range 1−17.2
Joshi et al. BMC Cancer  (2015) 15:546 Page 5 of 12
Ki67 {P = 0.049, HR = 0.53 (0.28−1.01); log-rank test
showing 95 % confidence intervals} (Additional file 1A)
having the weakest prognostic value, MCM2 the stron-
gest {P = 0.0148, HR = 0.35 (0.15−0.85); log-rank test
showing 95 % confidence intervals} (Additional file 1B),
followed by Geminin {P = 0.0254, HR = 0.47 (0.24−0.93);
log-rank test showing 95 % confidence intervals}
(Additional file 1C).
To examine the utility of these markers as inde-
pendent predictors of survival, we also performed
multivariable Cox regression analysis with backward
stepwise regression, and found only high histological
grade {P = 0.0502, HR = 1.84 (1–3.38)} and lymph
node-positive status {P = 0.0006, HR = 3.9 (1.79−8.5)}
to be associated with breast cancer-related death within
15 years for all breast cancers irrespective of ER positivity
(Table 5). Among ER-positive cases, again only lymph
node-positive status {P = 0.0006, HR = 7.13 (2.32−21.89)}
remained significantly associated with BCSS following a
multivariable analysis (Additional file 2).
Discussion
We have assessed TMAs of 309 cases of primary inva-
sive breast cancers for the expression of the proliferation
markers Ki67, MCM2 and Geminin by IHC using con-
ventional light microscopy and by digital imaging. We
observed a significantly positive correlation between the
methodologies in assessing all the 3 biomarkers confirm-
ing that remote assessment of scanned images is com-
parable with using light microscopy to score histological
glass slides.
The methodological aspects of immunohistochemistry
are being increasingly standardised as a consequence of
the widespread uptake of automated systems that im-
prove consistency. By extending this approach to include
digital imaging and computer-aided systems it may be
possible to confer greater objectivity to methods of im-
munohistochemical scoring [27]. In agreement with our
findings, and with a view to implementing these
changes, Konsti et al. have developed a virtual micros-
copy and automated analysis platform, which showed
87 % agreement and a weighted kappa value of 0.57
when compared to visual assessment of Ki67 immuno-
histochemical expression in breast cancer [28]. Digital
microscopy for scoring of scanned images of the TMAs,
a high-throughput method, has advantages over the con-
ventional light microscopic method. These include ease
of handling compared to manual navigation of a TMA
slide: for example, the linking of cores to the predefined
TMA ‘map’ ensures that the core/case are accurately
identified and recorded. In addition, the samples can be
accessed and evaluated remotely through any computer
Table 3 Immunohistochemical expression of Ki67, MCM2 and Geminin in 309 cases of early breast cancer as assessed by light
microscope and digital imaging and the correlation between the two methods of scoring
Marker Score Conventional method of scoring Digital method of scoring Correlation
Available values Max Min Median Available values Max Min Median Spearman’s co-efficient
Ki67 Maximum of the 3 cores 258 95 0 10 175 97 0 7 n = 174a
0.90 (0.86−0.92)
p < 0.001
Average of the 3 cores 258 90 0 7.7 175 85.33 0 4.5 n = 174a
0.91 (0.88−0.93)
p < 0.001
MCM2 Maximum of the 3 cores 260 100 0 30 167 100 0 37 n = 167a
0.92 (0.90−0.94)
p < 0.001
Average of the 3 cores 260 100 0 24 167 98.5 0 27 n = 167a
0.94 (0.91−0.95)
p < 0.001
Geminin Maximum of the 3 cores 258 40 0 5 270 62 0 2 n = 257
0.88 (0.85−0.91)
p < 0.001
Average of the 3 cores 258 28.3 0 3 270 37 0 2 n = 257
0.90 (0.87−0.92)
p < 0.001
aThe number of cores available for digital scoring was not the same as the number available for scoring conventionally. Hence, only those scored by both
techniques were compared with each other
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without the need for availability of a light microscope
and thus this method provides an opportunity to ex-
change information between observers, such as the
double-reading of slides (particularly valuable for clinical
trial material), with ease. Voros et al. used a partially
digitised counting method for Ki67, and concluded that
such a technique was faster, more convenient and would
significantly improve the reproducibility of using Ki67 as
a proliferation marker in breast cancer [29].
In this study, we do not report digital image analysis
of the cases using computer software but describe the
scoring of proliferation marker-stained scanned images
by human observers. One of the goals of automated
image analysis would be to improve the accuracy and re-
producibility in scoring biomarkers such as Ki67, MCM2
and Geminin. Fasanella et al. used computer-assisted
image analysis of digitised slides, and found manual and
automated methods to be comparable in assessing Ki67
expression in breast cancer [8, 30]. However, in our
opinion, further work is required before automated
image analysis can be widely adopted for the determin-
ation of proliferation marker frequency in invasive breast
cancer patients although our results hint at the potential
advantages and non-inferiority to the assessment of
digital images over conventional means.
We encountered some recurring questions on the ap-
proach to, and methodology of, immunohistochemistry
in the TMA setting. TMA technology has been widely
used in research and some guidelines for practice are
now available [31]. Nonetheless, there are some unre-
solved issues including the optimum number of cores to
be assessed, the extraction of a per-sample score from
values obtained from multiple cores (maximum or aver-
age), and the calculation of an optimal cut-off for prog-
nostication. For Ki67, we found the average score from
two cores to be highly correlated with the average score
from three cores. For this marker, using either the aver-
age or the maximum from the three cores as the final
score, we found little difference in their association to
clinico-pathological features, implying that either would
be appropriate. Moreover, we observed no significant
inter-core variability in Ki67 and MCM2 expression, al-
though Geminin expression differed significantly among
the 3 cores. We conclude that for each biomarker study,
A B
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L
Fig. 1 Expression of proliferation markers in invasive breast cancers. Representative breast cancer cores from a consecutive TMAs showing low
and high immunohistochemical staining for 3 proliferation markers Ki67 (a,b), MCM2 (e,f) and Geminin (i,j) (150X magnification). Distribution of
IHC determined expression of Ki67 (c), MCM2 (g) and Geminin (k) across 309 primary breast carcinomas. The number of cases is indicated on the
x-axis, while the percentage scoring for the respective marker is depicted in the y-axis. Correlation between light microscopic and digital image
guided scores for Ki67 (d), MCM2 (h) and Geminin (l). The Spearman’s rank correlation coefficient and p-values are shown
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similar analyses are required to evaluate the number of
cores required for assessment of that specific lesion, and
indeed whether that specific marker can be reliably de-
termined from TMAs at all. Biomarkers with low
level expression (such as Geminin) may not be ap-
propriate for TMA studies since reproducible scores
from small samples are more problematic than for
markers expressed at consistently higher levels (such
as MCM2). As a general principle, multiple cores
need to be assessed in an attempt to simulate the
whole slide and all the representative areas. IHC
scoring of a single 1 mm TMA core for ER/PR/
HER2 was found to be sufficient, without significant
heterogeneity by Kyndi and colleagues [32]. Similarly,
estimation of Ki67 using TMAs has been proven to
have good concordance with whole section assess-
ment [33]. In practice, most studies, including ours,
indicate that triplicate core assessment using a
0.6 mm core size is sufficient for the accurate evalu-
ation of Ki67 and also MCM2 in invasive breast can-
cer tissue [33, 34].
Different methods of calculating cut-off values for sur-
vival analysis have been attempted in the literature, in-
cluding the dataset median or mean, a literature-
informed value, or an even more arbitrary value [8]. The
clinical utility of proliferation marker immunohisto-
chemistry has been largely hampered by the lack of con-
sensus with respect to the cut-off used. In a review by
Luporsi and colleagues, Ki67 cut points were distributed
between 5 and 38 %, with most studies using a cut-off
between 10 and 20 % [10]. A multivariable analysis by
Tashima et al. to determine the optimal cut-off for Ki67
revealed 20 % to be the optimal value [35]. In this study,
we used time-dependent ROC curves to find the cut-off
that yielded the highest balanced accuracy for 15-year
BCSS in this patient cohort [25]. The cut-offs we found
were lower than those reported in much of the litera-
ture. This may reflect our own patient cohort. In
addition, the optimal values we report are those we have
found to be associated with BCSS as opposed to overall
survival (OS) or disease-free survival (DFS), both of
which are vulnerable to confounding factors and which
are the outcomes reported in other series [36].
As expected, we found ER-negative and high grade
tumours to have significantly higher proliferation indi-
ces for all 3 markers [37]. Ki67 expression was also
significantly associated with tumour size and patient
age although none of the three proliferation markers
were associated with lymph node or HER2 status (for
the number of cases for whom HER2 status was avail-
able). These findings are consistent with those from
most studies of proliferation markers in breast and
other cancers [9].
The proliferation status of a tumour gives an estimate
of the rate at which tumour cells enter the cell cycle,
which reflects the rate of tumour growth. Ki67 is
expressed from late G1 to M phase, MCM2 in all phases
and Geminin in the S-G2-M phases of the cell cycle
(Fig. 3). This theoretically makes MCM2 a much more
sensitive marker of proliferation, since it detects cells
that are “licensed to proliferate” and capable of initiating
DNA replication [18]. In contrast, Geminin is a more
Table 4 Association between the proliferation markers Ki67, MCM2 and Geminin and other prognostic factors in 309 cases of early
breast cancer
Clinico-pathological Feature Categories Ki67 median p-value MCM2 median p-value Geminin Median p- value
Agea </= 50 years 10 0.006 31.6 0.097 3.4 0.101
>50 years 7 21.3 3
Gradeb 1 4.5 <0.001 16.5 <0.001 0.5 <0.001
2 7 20.7 2.7
3 14.7 50 6.3
ER statusa Positive 6.7 <0.001 19.1 <0.001 2.3 <0.001
Negative 14.6 50 8.1
LN statusa Positive 7.5 0.787 24 0.734 3 0.387
Negative 8 24.67 3
HER2ac status Positive 9 0.299 30 0.298 3 0.039
Negative 12.7 37 8.3
Tumour sizeb </= 2 cm 7.5 0.034 23.4 0.197 2.6 0.132
>2, < 5 cm 7.1 24.3 3
>/= 5 cm 14.5 37.5 5.7
aMann Whitney test used to test the association between 2 continuous, unpaired variables
bKruskal-Wallis test used to test the association among 3 continuous, unpaired variables
cOnly 155 cases with known HER2 status were included to test the association of HER2 status with each of the proliferation markers
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specific marker of proliferation, as it only detects cells
that are “committed to proliferate” [38]. MCM2 has a
significantly higher frequency of expression in breast
cancer nuclei than Ki67 and Geminin. Of note, we found
MCM2 to be a more robust and sensitive prognostic
marker than Ki67 and Geminin in a univariable survival
model, which could be a consequence of these markers
being differentially expressed during the cell cycle. In
A B
C D
E F
Fig. 2 Univariable breast cancer-specific analyses among 309 invasive breast carcinomas. Kaplan Meier curves showing breast cancer-specific
survival (BCSS) in relation to high (solid line) and low (dotted line) expression of Ki67 (a), MCM2 (c) and Geminin (e). The cut-offs of percentage
expression were 8, 12 and 2.33 for Ki67, MCM2 and Geminin, respectively. Log rank p-values are stated. The number of patients at risk for every
2.5 years is given for each subgroup. Using time-dependent Receiver Operating Characteristic (ROC) curves for 15-year BCSS, optimal cut-offs were
calculated for Ki67 (b), MCM2 (d) and Geminin (f)
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agreement with our findings, Gonzalez et al. found the
MCM2 labelling index to be significantly associated with
overall survival and disease free survival in breast cancer
and, indeed, that MCM2 was independent of, and super-
ior to, histological grade, Ki67 labelling index and lymph
node stage in determining prognosis in a multivariable
analysis [20]. Similarly, in a study of oral cavity squa-
mous cell carcinoma, Szelachowska et al. found MCM2
to be prognostically superior to Ki67 in predicting 5-
year OS [39] whereas the findings of Rodins et al. dem-
onstrated MCM2 to be a better marker of proliferation
than Ki67 in normal renal epithelial cells and in different
types of renal tumours, with Ki67 significantly underesti-
mating the number of dividing cells [40]. A number of
studies have shown MCM2 expression to be a signifi-
cant prognostic marker in other tumour types includ-
ing oesophageal [41] and laryngeal squamous cell
carcinoma [42] and oligodendroglioma of the brain
[43]. One possible explanation for these observations
is the low expression of Ki67 in early G1 phase,
which leads to the fraction of cells at this stage of
the cell cycle being missed [40]. It thus remains un-
clear why Ki67 is so utilised in prognostication in
invasive breast cancer and other tumours whilst
MCM2 is not routinely used.
One potential shortcoming of our study was that all
operable, invasive breast cancer cases were included.
Subgroup analyses where the assessment of proliferation
may be most clinically relevant, for example, of tumours
that were lymph node-negative and hormone receptor-
positive were not attempted since there were fewer than
100 cases available in our series. One established cut-off
for Ki67, as defined by St Gallen’s guidelines, is 14 % but
this is derived from data on hormone receptor-positive
patients. We applied this cut-off in our entire dataset
and found the two groups of high versus low expressers
had significantly different survivals (data not shown) but
our series included both receptor negative and positive
disease. In this setting therefore we sought to identify an
optimum cut-off for a consecutive cohort of all these op-
erable invasive breast cancers.
Although MCM2 appeared to be more strongly associ-
ated with BCSS in a univariable analysis than Ki67, none
of the three proliferation biomarkers were independent
predictors of survival in a multivariable analysis of the
Table 5 Univariable and multivariable analyses of prognostic factors for 15-year breast cancer specific survival in 309 cases of early,
invasive breast cancer
Prognostic factor Univariable Cox regression analysis Multivariable Cox regression analysis
HR 95 % CI p-value HR 95 % CI p-value
Ki67: low 0.55 0.34−0.89 0.014 1.38 0.56−3.38 0.485
MCM2: low 0.27 0.12−0.59 0.0004 0.352 0.07−1.85 0.218
Geminin: low 0.51 0.31−0.84 0.007 0.824 0.34−2.02 0.673
Histological grade: 3 1.95 1.41−2.69 <0.0001 1.42 0.68−2.96 0.346
ER status: positive 0.32 0.2−0.5 <0.0001 0.737 0.32−1.72 0.48
HER2 status: positive 1.65 0.84−3.25 0.143 0.545 0.2−1.5 0.241
LN status: positive 3.35 1.98−5.66 <0.0001 3.44 1.54−7.72 0.002
Age > 50 year 0.85 0.53−1.34 0.477 1.36 0.63−2.91 0.431
Tumour size: medium 0.76 0.23−2.49 0.891 1.38 0.16−12 0.772
Tumour size: small 0.8 0.25−2.6 0.891 2.84 0.32−25.35 0.35
After backward stepwise regression
Grade: 3 1.84 1−3.38 0.0502
LN status: positive 3.9 1.79−8.5 0.0006
Fig. 3 Differential expressions of the three proliferation markers
during the cell cycle. Ki67’s expression (shown with a blue line) is
detectable from late G1 to M phase. MCM2 (red line) is present in all
cell cycle phases. Geminin (green line) is expressed only in the G2-M
phase making it a more specific but less sensitive marker
of proliferation
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whole cohort or of the ER positive sub-population.
Lymph node positivity in this series was the most im-
portant prognosticator. The greatest utility of assessing
proliferation markers may be limited to good prognosis,
receptor-positive sub-populations of patients and the
clinical utility to select those who are likely to benefit
from adjuvant chemotherapy. Of note, different cut-offs
may need to be applied to differing sub-types of invasive
breast carcinomas to maximise the clinical benefit of de-
termination of proliferation marker expression, which is
unlikely to be a ‘one size fits all’. However, there were in-
sufficient patients in this good prognosis sub-group for
such an approach to be confirmed in the present study.
Inter-observer variation is another critical issue with
immunohistochemistry although most studies have
shown a good concordance rate. We did not assess
inter-observer variation in our study, although there was
a general agreement regarding the score amongst the au-
thors. Rather, we focussed on assessing the concordance
between scoring by conventional microscopy and by the
digital images from the same sections. In the routine set-
ting, inter-observer variation is a potential issue in IHC
analyses. Digital imaging with automated scoring may be
able to reduce the variability of scoring of IHC. Further
research and development into such systems is urgently
required.
Conclusions
We have shown that digital microscopy images can be
used as a high-throughput technique for assessing the im-
munohistochemical expression of proliferation markers in
early invasive breast cancer with results that are compar-
able to those from light microscopy-based scoring. We
used MCM2, Ki67 and Geminin, and found MCM2 to be
the most sensitive marker of proliferation and prognosis
among the three. Despite not finding these three markers
to be independently prognostic of BCSS as evinced by our
multivariable analysis, digital microscopy-based assess-
ment of these and others may yet find utility in particular
subgroups of breast cancer patients, for example in lymph
node-negative, hormone receptor-positive patients, which
have generally better prognoses. Future studies using im-
munohistochemistry should be directed towards utility of
Ki67 and MCM2 in choosing the appropriate adjuvant
therapy in early breast cancer cases.
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